Status:
UNKNOWN
Ventilatory Efficiency in Critically Ill COVID-19 Patients
Lead Sponsor:
ASST Fatebenefratelli Sacco
Collaborating Sponsors:
Ospedale Infermi Rimini
S. Anna Hospital
Conditions:
ARDS
Eligibility:
All Genders
18-90 years
Brief Summary
The new severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2) causes the illness named COVID-19, which is primarily characterized by pneumonia. As of 27 December, there have been over 79.2 m...
Eligibility Criteria
Inclusion
- All of the following:
- confirmed SARS-CoV-2 infection by RT-PCR on a nasopharyngeal swab
- severe hypoxemia due to COVID-19 who meets the diagnostic criteria of ARDS (Berlin's definition)
- invasive mechanical ventilation
- patients receiving neuromuscular blocking drugs
Exclusion
- history of preexisting severe hypoxemia (i.e. primary pulmonary hypertension, COPD in therapy with O2 supplementation, pulmonary fibrosis, etc.)
- severe haemodynamic instability defined as:
- Mean arterial pressure \< 65 mmHg despite the infusion of norepinephrine, or epinephrine, or dobutamine, or levosimendan
- severe left ventricular dysfunction with ejection fraction \<20%
- right ventricular failure due to pulmonary embolism
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 15 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04694742
Start Date
September 1 2020
End Date
April 15 2021
Last Update
January 5 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Arcispedale Sant'Anna
Ferrara, Emilia-Romagna, Italy, 44124
2
Ospedale Infermi
Rimini, Emilia-Romagna, Italy, 47923
3
ASST Fatebenefratelli Sacco
Milan, Lombardy, Italy, 20157
4
Azienda Ospedaliero Universitaria Ospedali Riuniti
Ancona, The Marches, Italy, 60126